Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

 $Introduced \ o1/o7/96 \ \ Origin: Appendix \ 5 \ \ Amended \ o1/o7/98, \ o1/o9/99, \ o1/o7/oo, \ 30/o9/o1, \ 11/o3/o2, \ o1/o1/o3, \ 24/10/o5, \ o1/o8/12, \ o4/o3/13$

| 27 164 | 4 440 859 | | | |
|--------|---|---|--|--|
| We (t | We (the entity) give ASX the following information. | | | |
| | 1 - All issues ust complete the relevant sections (attac | h sheets if there is not enough space). | | |
| 1 | *Class of *securities issued or to be issued | Fully paid ordinary shares | | |
| 2 | Number of *securities issued or to be issued (if known) or maximum number which may be issued | 100,000,000 | | |
| 3 | Principal terms of the *securities (e.g. if options, exercise price and expiry date; if partly paid *securities, the amount outstanding and due dates for payment; if *convertible securities, the conversion price and dates for conversion) | Fully paid ordinary shares | | |

Name of entity
Schrole Group Ltd

⁺ See chapter 19 for defined terms.

| 4 | Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities? | Yes |
|----|--|--|
| | If the additional *securities do not rank equally, please state: • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment | |
| 5 | Issue price or consideration | \$0.008 (0.8 cents) per share |
| 6 | Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets) | To raise additional funds to increase the Company's business development and in-house software development capability to support the rollout of strategic initiatives, including launching new revenue generating products |
| 6a | Is the entity an *eligible entity that has obtained security holder approval under rule 7.1A? If Yes, complete sections 6b – 6h in relation to the *securities the subject of this Appendix 3B, and comply with section 6i | No, the entity's 7.1A placement capacity expired on 23 May 2019 |
| 6b | The date the security holder resolution under rule 7.1A was passed | N/A |
| 6c | Number of *securities issued without security holder approval under rule 7.1 | Nil |
| 6d | Number of *securities issued with security holder approval under rule 7.1A | Nil |

6e Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)

100,000,000 Date of meeting: 24th September 2019

6f Number of *securities issued under an exception in rule 7.2

Nil

6g If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.

N/A

6h If *securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements

14/14

6i Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements

7.1: 131,143,035 7.1A: N/A Total: 131,143,035

7 +Issue dates

Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.

Cross reference: item 33 of Appendix 3B.

26th September 2019

- 8 Number and *class of all *securities quoted on ASX (*including* the *securities in section 2 if applicable)
- 9 Number and +class of all +securities not quoted on ASX (including the +securities in section 2 if applicable)

| Number | +Class |
|-------------|--|
| 654,316,176 | Fully paid ordinary shares |
| 233,304,055 | Fully paid ordinary shares escrowed for 24 months from quotation |

⁺ See chapter 19 for defined terms.

| 93,000,000 | B Class performance shares subject to Class B |
|-------------|---|
| | milestones as detailed in |
| | Prospectus dated 18 |
| | August 2017, expiring 5 |
| | years from issue, escrowed |
| | for 24 months from |
| | quotation |
| 150,000,000 | C Class performance |
| <i>y</i> | shares subject to Class C |
| | milestones as detailed in |
| | Prospectus dated 18 |
| | August 2017, expiring 5 |
| | years from issue, escrowed |
| | for 24 months from |
| | quotation |
| 4,720,000 | Performance Rights with a |
| | nil exercise price expiring |
| | 5 years from issue |
| 13,560,000 | Performance Rights with a |
| | nil exercise price and with |
| | Tranche B Performance |
| | Rights vesting conditions |
| | as detailed in the |
| | Company's prospectus |
| | dated 3 July 2018, expiring |
| | 5 years from issue |
| 22,600,000 | Performance Rights with a |
| | nil exercise price and with |
| | Tranche C Performance |
| | Rights vesting conditions |
| | as detailed in the |
| | Company's prospectus |
| | dated 3 July 2018, expiring |
| | 5 years from issue |
| 25,707,927 | Vendor options with |
| | exercise price of \$0.04 and |
| | expiring 3 years from issue |
| | date, escrowed for 24 |
| | months from quotation. |

| Number | ⁺ Class |
|------------|------------------------------|
| 71,292,073 | Unlisted options with |
| | exercise price of \$0.04 and |
| | expiring 3 years from issue |
| | date, escrowed for 12 |
| | months from issue; |
| 28,250,000 | Unlisted options with |
| | exercise price of \$0.02, |
| | expiring 3 years from issue |
| | date, escrowed for 24 |
| | months from quotation |
| 50,000,000 | Unlisted options with |
| | exercise price of \$0.03, |
| | expiring 3 years from issue |
| | date, escrowed for 24 |
| | months from quotation |
| 21,750,000 | Unlisted options with |
| | exercise price of 0.02, |
| | expiring 3 years from |
| | quotation, escrowed for 12 |
| | months from issue |
| 7,000,000 | Unlisted options with |
| | exercise price of \$0.03, |
| | expiring 3 years after issue |
| | date, escrowed for 24 |
| | months from quotation |
| 7,000,000 | Unlisted options with |
| | exercise price of \$0.04 |
| | (and vesting only if 10-day |
| | VWAP of the Company's |
| | share is \$0.04), expiring 3 |
| | years after issue date, |
| | escrowed 24 months from |
| | quotation |

Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)



Part 2 - Pro rata issue - NOT APPLICABLE

Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities

- Type of *securities (tick one)
- (a) +Securities described in Part 1

⁺ See chapter 19 for defined terms.

| (b) | All other ⁺ securities |
|-----|--|
| | Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible |
| | securities |

Entities that have ticked box 34(a)

Additional securities forming a new class of securities

| Fick to locum | te you are providing the information or |
|------------------|---|
| 35 | If the *securities are *equity securities, the names of the 20 largest holders of the additional *securities, and the number and percentage of additional *securities held by those holders |
| 36 | If the *securities are *equity securities, a distribution schedule of the additional *securities setting out the number of holders in the categories 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over |
| 37 | A copy of any trust deed for the additional *securities |

Entities that have ticked box 34(b) – questions 38-42 not applicable

Quotation agreement

- [†]Quotation of our additional [†]securities is in ASX's absolute discretion. ASX may quote the [†]securities on any conditions it decides.
- 2 We warrant the following to ASX.
 - The issue of the *securities to be quoted complies with the law and is not for an illegal purpose.
 - There is no reason why those *securities should not be granted *quotation.
 - An offer of the *securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

• Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any *securities to be quoted and that no-one has any right to return any *securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the *securities be quoted.

- If we are a trust, we warrant that no person has the right to return the *securities to be quoted under section 1019B of the Corporations Act at the time that we request that the *securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before †quotation of the †securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

| Sign here: | (Director/ Company secretary) | Date: | 26 September 2019 |
|-------------|---|-------|-------------------|
| Print name: | Nick Allan | | |
| | == == == == | | |

⁺ See chapter 19 for defined terms.